Skip to main content
Top
Published in: BMC Infectious Diseases 1/2022

Open Access 01-12-2022 | Acute Otitis Media | Research

Incidence of acute otitis media in children in the United States before and after the introduction of 7- and 13-valent pneumococcal conjugate vaccines during 1998–2018

Authors: Tianyan Hu, Nicolae Done, Tanaz Petigara, Salini Mohanty, Yan Song, Qing Liu, Esteban Lemus-Wirtz, James Signorovitch, Eric Sarpong, Thomas Weiss

Published in: BMC Infectious Diseases | Issue 1/2022

Login to get access

Abstract

Background

Acute otitis media (AOM) is a leading cause of office visits and antibiotic prescriptions in children. Pneumococcal conjugate vaccines were introduced in the USA in 2000 (7-valent, PCV7) and 2010 (13-valent, PCV13). Expanded valency PCVs are currently under development. To describe the impact of PCVs and quantify the residual burden of AOM, this study estimated annual incidence rates (IRs) of AOM and AOM-related complications and surgical procedures in children < 18 years in the USA before and after the introduction of PCV7 and PCV13.

Methods

AOM episodes were identified in the IBM MarketScan® Commercial and Medicaid databases using diagnosis codes (ICD-9-CM: 382.x; ICD-10-CM: H66.xx and H67.xx). Annual IRs were calculated as the number of episodes per 1000 person-years (PYs) for all children < 18 years and by age group (< 2, 2–4, and 5–17 years). National estimates of annual AOM IRs were extrapolated using Census Bureau data. Interrupted time series analyses were used to assess immediate and gradual changes in monthly AOM IRs, controlling for seasonality.

Results

In the commercially insured population, AOM IRs declined between the pre-PCV7 period (1998–1999) and the late PCV13 period (2014–2018) from 1170.1 to 768.8 episodes per 1000 PY for children < 2 years, from 547.4 to 410.3 episodes per 1000 PY in children 2–4 years, and from 115.6 to 91.8 episodes per 1000 PY in children 5–17 years. The interrupted time series analyses indicated significant immediate or gradual decreases in the early PCV7 period (2001–2005), and gradual increases in the late PCV7 period (2006–2009) in children < 2 years; however, crude IRs trended downward in all time periods. In older children, IRs decreased in the early PCV7 and early PCV13 period (2011–2013), but gradually increased in the late PCV7 period. IRs of AOM-related surgical procedures decreased, and IRs of AOM-related complications increased during the study timeframe.

Conclusions

AOM disease burden remains high in children of all ages despite overall reductions in AOM IRs during 1998–2018 following the introduction of PCV7 and PCV13. The impact of investigational PCVs on the disease burden of AOM will likely depend on AOM etiology and circulating pneumococcal serotypes.
Appendix
Available only for authorised users
Footnotes
1
Medicaid is a joint federal and state program that, along with the Children’s Health Insurance Program (CHIP), provides health and long-term coverage to low-income people in the United States. While eligibility rules vary by state, Medicaid typically covers children, pregnant women, elderly adults and people with disabilities, and eligible low-income adults. Medicaid is managed by each state and funded jointly by the federal and state governments. Many Medicaid enrollees receive care through private managed care plans contracted by the Medicaid program in their state. Because Medicaid programs in general pay lower rates than private health insurance plans, some providers (including hospitals) choose not to accept Medicaid patients or to accept only a limited number of such patients. However, in general the same providers can be accessible to both Medicaid and privately insured patients. Moreover, as a person’s income may change, they may lose (and subsequently regain) Medicaid eligibility, known as “churning.” Medicaid also tends to have a disproportionately larger share of black and Hispanic people compared to private plans.
 
Literature
1.
go back to reference Venekamp RP, Damoiseaux RA, Schilder AG. Acute otitis media in children. Am Fam Physician. 2017;95(2):109–10.PubMed Venekamp RP, Damoiseaux RA, Schilder AG. Acute otitis media in children. Am Fam Physician. 2017;95(2):109–10.PubMed
2.
go back to reference Qureishi A, Lee Y, Belfield K, Birchall JP, Daniel M. Update on otitis media—prevention and treatment. Infect Drug Resist. 2014;7:15–24.PubMedPubMedCentral Qureishi A, Lee Y, Belfield K, Birchall JP, Daniel M. Update on otitis media—prevention and treatment. Infect Drug Resist. 2014;7:15–24.PubMedPubMedCentral
3.
go back to reference Kaur R, Morris M, Pichichero ME. Epidemiology of acute otitis media in the postpneumococcal conjugate vaccine era. Pediatrics. 2017;140(3):e20170181.CrossRef Kaur R, Morris M, Pichichero ME. Epidemiology of acute otitis media in the postpneumococcal conjugate vaccine era. Pediatrics. 2017;140(3):e20170181.CrossRef
4.
go back to reference Talathi S, Gupta N, Sethuram S, Khanna S, Sitnitskaya Y. Otitis media in fully vaccinated preschool children in the pneumococcal conjugate vaccine era. Glob Pediatr Health. 2017;4:2333794X17749668.PubMedPubMedCentral Talathi S, Gupta N, Sethuram S, Khanna S, Sitnitskaya Y. Otitis media in fully vaccinated preschool children in the pneumococcal conjugate vaccine era. Glob Pediatr Health. 2017;4:2333794X17749668.PubMedPubMedCentral
6.
go back to reference Masomian M, Ahmad Z, Ti Gew L, Poh CL. Development of next generation Streptococcus pneumoniae vaccines conferring broad protection. Vaccines (Basel). 2020;8(1):132.CrossRef Masomian M, Ahmad Z, Ti Gew L, Poh CL. Development of next generation Streptococcus pneumoniae vaccines conferring broad protection. Vaccines (Basel). 2020;8(1):132.CrossRef
7.
go back to reference Advisory Committee on Immunization Practices. Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2000;49(RR-9):1–35. Advisory Committee on Immunization Practices. Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2000;49(RR-9):1–35.
8.
go back to reference Suaya JA, Gessner BD, Fung S, Vuocolo S, Scaife J, Swerdlow DL, et al. Acute otitis media, antimicrobial prescriptions, and medical expenses among children in the United States during 2011–2016. Vaccine. 2018;36(49):7479–86.CrossRef Suaya JA, Gessner BD, Fung S, Vuocolo S, Scaife J, Swerdlow DL, et al. Acute otitis media, antimicrobial prescriptions, and medical expenses among children in the United States during 2011–2016. Vaccine. 2018;36(49):7479–86.CrossRef
9.
go back to reference Zhou F, Shefer A, Kong Y, Nuorti JP. Trends in acute otitis media-related health care utilization by privately insured young children in the United States, 1997–2004. Pediatrics. 2008;121(2):253–60.CrossRef Zhou F, Shefer A, Kong Y, Nuorti JP. Trends in acute otitis media-related health care utilization by privately insured young children in the United States, 1997–2004. Pediatrics. 2008;121(2):253–60.CrossRef
10.
go back to reference Marom T, Tan A, Wilkinson GS, Pierson KS, Freeman JL, Chonmaitree T. Trends in otitis media-related health care use in the United States, 2001–2011. JAMA Pediatr. 2014;168(1):68–75.CrossRef Marom T, Tan A, Wilkinson GS, Pierson KS, Freeman JL, Chonmaitree T. Trends in otitis media-related health care use in the United States, 2001–2011. JAMA Pediatr. 2014;168(1):68–75.CrossRef
11.
go back to reference Kawai K, Adil EA, Barrett D, Manganella J, Kenna MA. Ambulatory visits for otitis media before and after the introduction of pneumococcal conjugate vaccination. J Pediatr. 2018;201:122–7.CrossRef Kawai K, Adil EA, Barrett D, Manganella J, Kenna MA. Ambulatory visits for otitis media before and after the introduction of pneumococcal conjugate vaccination. J Pediatr. 2018;201:122–7.CrossRef
12.
go back to reference Grijalva CG, Poehling KA, Nuorti JP, Zhu Y, Martin SW, Edwards KM, et al. National impact of universal childhood immunization with pneumococcal conjugate vaccine on outpatient medical care visits in the United States. Pediatrics. 2006;118(3):865–73.CrossRef Grijalva CG, Poehling KA, Nuorti JP, Zhu Y, Martin SW, Edwards KM, et al. National impact of universal childhood immunization with pneumococcal conjugate vaccine on outpatient medical care visits in the United States. Pediatrics. 2006;118(3):865–73.CrossRef
13.
go back to reference Zhou X, de Luise C, Gaffney M, Burt CW, Scott DA, Gatto N, et al. National impact of 13-valent pneumococcal conjugate vaccine on ambulatory care visits for otitis media in children under 5 years in the United States. Int J Pediatr Otorhinolaryngol. 2019;119:96–102.CrossRef Zhou X, de Luise C, Gaffney M, Burt CW, Scott DA, Gatto N, et al. National impact of 13-valent pneumococcal conjugate vaccine on ambulatory care visits for otitis media in children under 5 years in the United States. Int J Pediatr Otorhinolaryngol. 2019;119:96–102.CrossRef
14.
go back to reference Tong S, Amand C, Kieffer A, Kyaw MH. Trends in healthcare utilization and costs associated with acute otitis media in the United States during 2008–2014. BMC Health Serv Res. 2018;18(1):318.CrossRef Tong S, Amand C, Kieffer A, Kyaw MH. Trends in healthcare utilization and costs associated with acute otitis media in the United States during 2008–2014. BMC Health Serv Res. 2018;18(1):318.CrossRef
15.
go back to reference Greenberg D, Hoover PA, Vesikari T, Peltier C, Hurley DC, McFetridge RD, et al. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants. Vaccine. 2018;36(45):6883–91.CrossRef Greenberg D, Hoover PA, Vesikari T, Peltier C, Hurley DC, McFetridge RD, et al. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants. Vaccine. 2018;36(45):6883–91.CrossRef
16.
go back to reference Platt HL, Greenberg D, Tapiero B, Clifford RA, Klein NP, Hurley DC, et al. A phase II trial of safety, tolerability and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in healthy infants. Pediatr Infect Dis J. 2020;39(8):763–70.CrossRef Platt HL, Greenberg D, Tapiero B, Clifford RA, Klein NP, Hurley DC, et al. A phase II trial of safety, tolerability and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in healthy infants. Pediatr Infect Dis J. 2020;39(8):763–70.CrossRef
17.
go back to reference Pfizer announces positive preliminary results from a proof-of-concept phase 2 study (B7471003) of its 20-valent pneumococcal conjugate vaccine candidate being investigated for the prevention of invasive disease and otitis media in healthy infants [press release]. September 09, 2019 2019. Pfizer announces positive preliminary results from a proof-of-concept phase 2 study (B7471003) of its 20-valent pneumococcal conjugate vaccine candidate being investigated for the prevention of invasive disease and otitis media in healthy infants [press release]. September 09, 2019 2019.
18.
go back to reference Pontefract B, Nevers M, Fleming-Dutra KE, Hersh A, Samore M, Madaras-Kelly K, editors. Diagnosis and antibiotic management of otitis media and otitis externa in United States Veterans. Open Forum Infect Dis; 2019: Oxford University Press USA. Pontefract B, Nevers M, Fleming-Dutra KE, Hersh A, Samore M, Madaras-Kelly K, editors. Diagnosis and antibiotic management of otitis media and otitis externa in United States Veterans. Open Forum Infect Dis; 2019: Oxford University Press USA.
19.
go back to reference Pichichero M, Kaur R, Scott DA, Gruber WC, Trammel J, Almudevar A, et al. Effectiveness of 13-valent pneumococcal conjugate vaccination for protection against acute otitis media caused by Streptococcus pneumoniae in healthy young children: a prospective observational study. Lancet Child Adolesc Health. 2018;2(8):561–8.CrossRef Pichichero M, Kaur R, Scott DA, Gruber WC, Trammel J, Almudevar A, et al. Effectiveness of 13-valent pneumococcal conjugate vaccination for protection against acute otitis media caused by Streptococcus pneumoniae in healthy young children: a prospective observational study. Lancet Child Adolesc Health. 2018;2(8):561–8.CrossRef
20.
go back to reference Lieberthal AS, Carroll AE, Chonmaitree T, Ganiats TG, Hoberman A, Jackson MA, et al. The diagnosis and management of acute otitis media. Pediatrics. 2013;131(3):e964–99.CrossRef Lieberthal AS, Carroll AE, Chonmaitree T, Ganiats TG, Hoberman A, Jackson MA, et al. The diagnosis and management of acute otitis media. Pediatrics. 2013;131(3):e964–99.CrossRef
21.
go back to reference Jokinen J, Palmu AA, Kilpi T. Acute otitis media replacement and recurrence in the Finnish otitis media vaccine trial. Clin Infect Dis. 2012;55(12):1673–6.CrossRef Jokinen J, Palmu AA, Kilpi T. Acute otitis media replacement and recurrence in the Finnish otitis media vaccine trial. Clin Infect Dis. 2012;55(12):1673–6.CrossRef
22.
go back to reference Hausdorff WP, Van Dyke MK, Van Effelterre T. Serotype replacement after pneumococcal vaccination. Lancet. 2012;379(9824):1387–8.CrossRef Hausdorff WP, Van Dyke MK, Van Effelterre T. Serotype replacement after pneumococcal vaccination. Lancet. 2012;379(9824):1387–8.CrossRef
23.
go back to reference Van Effelterre T, Moore MR, Fierens F, Whitney CG, White L, Pelton SI, et al. A dynamic model of pneumococcal infection in the United States: implications for prevention through vaccination. Vaccine. 2010;28(21):3650–60.CrossRef Van Effelterre T, Moore MR, Fierens F, Whitney CG, White L, Pelton SI, et al. A dynamic model of pneumococcal infection in the United States: implications for prevention through vaccination. Vaccine. 2010;28(21):3650–60.CrossRef
24.
go back to reference Murphy TF. Vaccines for nontypeable Haemophilus influenzae: the future is now. Clin Vaccine Immunol. 2015;22(5):459–66.CrossRef Murphy TF. Vaccines for nontypeable Haemophilus influenzae: the future is now. Clin Vaccine Immunol. 2015;22(5):459–66.CrossRef
25.
go back to reference Casey JR, Adlowitz DG, Pichichero ME. New patterns in the otopathogens causing acute otitis media six to eight years after introduction of pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2010;29(4):304.CrossRef Casey JR, Adlowitz DG, Pichichero ME. New patterns in the otopathogens causing acute otitis media six to eight years after introduction of pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2010;29(4):304.CrossRef
26.
go back to reference Casey JR, Kaur R, Friedel VC, Pichichero ME. Acute otitis media otopathogens during 2008–2010 in Rochester NY. Pediatr Infect Dis J. 2013;32(8):805.CrossRef Casey JR, Kaur R, Friedel VC, Pichichero ME. Acute otitis media otopathogens during 2008–2010 in Rochester NY. Pediatr Infect Dis J. 2013;32(8):805.CrossRef
27.
go back to reference Moore MR, Gertz J, Robert E, Woodbury RL, Barkocy-Gallagher GA, Schaffner W, Lexau C, et al. Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005. J Infect Dis. 2008;197(7):1016–27.CrossRef Moore MR, Gertz J, Robert E, Woodbury RL, Barkocy-Gallagher GA, Schaffner W, Lexau C, et al. Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005. J Infect Dis. 2008;197(7):1016–27.CrossRef
28.
go back to reference Pai R, Moore MR, Pilishvili T, Gertz RE, Whitney CG, Beall B, et al. Postvaccine genetic structure of Streptococcus pneumoniae serotype 19A from children in the United States. J Infect Dis. 2005;192(11):1988–95.CrossRef Pai R, Moore MR, Pilishvili T, Gertz RE, Whitney CG, Beall B, et al. Postvaccine genetic structure of Streptococcus pneumoniae serotype 19A from children in the United States. J Infect Dis. 2005;192(11):1988–95.CrossRef
29.
go back to reference Pelton SI, Huot H, Finkelstein JA, Bishop CJ, Hsu KK, Kellenberg J, et al. Emergence of 19A as virulent and multidrug resistant Pneumococcus in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2007;26(6):468–72.CrossRef Pelton SI, Huot H, Finkelstein JA, Bishop CJ, Hsu KK, Kellenberg J, et al. Emergence of 19A as virulent and multidrug resistant Pneumococcus in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2007;26(6):468–72.CrossRef
30.
go back to reference Pichichero ME, Casey JR. Emergence of a multiresistant serotype 19A pneumococcal strain not included in the 7-valent conjugate vaccine as an otopathogen in children. JAMA. 2007;298(15):1772–8.CrossRef Pichichero ME, Casey JR. Emergence of a multiresistant serotype 19A pneumococcal strain not included in the 7-valent conjugate vaccine as an otopathogen in children. JAMA. 2007;298(15):1772–8.CrossRef
31.
go back to reference Hinman AR, Orenstein WA, Santoli JM, Rodewald LE, Cochi SL. Vaccine shortages: history, impact, and prospects for the future. Annu Rev Public Health. 2006;27(1):235–59.CrossRef Hinman AR, Orenstein WA, Santoli JM, Rodewald LE, Cochi SL. Vaccine shortages: history, impact, and prospects for the future. Annu Rev Public Health. 2006;27(1):235–59.CrossRef
32.
go back to reference Siddiq S, Grainger J. The diagnosis and management of acute otitis media: American Academy of Pediatrics Guidelines 2013. Arch Dis Child Educ Pract Ed. 2015;100(4):193–7.CrossRef Siddiq S, Grainger J. The diagnosis and management of acute otitis media: American Academy of Pediatrics Guidelines 2013. Arch Dis Child Educ Pract Ed. 2015;100(4):193–7.CrossRef
33.
go back to reference Kaur R, Fuji N, Pichichero ME. Dynamic changes in otopathogens colonizing the nasopharynx and causing acute otitis media in children after 13-valent (PCV13) pneumococcal conjugate vaccination during 2015–2019. Eur J Clin Microbiol Infect Dis. 2021;41:37–44.CrossRef Kaur R, Fuji N, Pichichero ME. Dynamic changes in otopathogens colonizing the nasopharynx and causing acute otitis media in children after 13-valent (PCV13) pneumococcal conjugate vaccination during 2015–2019. Eur J Clin Microbiol Infect Dis. 2021;41:37–44.CrossRef
34.
go back to reference Kaur R, Pham M, Yu KOA, Pichichero ME. Rising pneumococcal antibiotic resistance in the post-13-valent pneumococcal conjugate vaccine era in pediatric isolates from a primary care setting. Clin Infect Dis Off Publ Infect Dis Soc Am. 2021;72(5):797–805.CrossRef Kaur R, Pham M, Yu KOA, Pichichero ME. Rising pneumococcal antibiotic resistance in the post-13-valent pneumococcal conjugate vaccine era in pediatric isolates from a primary care setting. Clin Infect Dis Off Publ Infect Dis Soc Am. 2021;72(5):797–805.CrossRef
35.
go back to reference Fireman B, Black SB, Shinefield HR, Lee J, Lewis E, Ray P. Impact of the pneumococcal conjugate vaccine on otitis media. Pediatr Infect Dis J. 2003;22(1):10–6.CrossRef Fireman B, Black SB, Shinefield HR, Lee J, Lewis E, Ray P. Impact of the pneumococcal conjugate vaccine on otitis media. Pediatr Infect Dis J. 2003;22(1):10–6.CrossRef
36.
go back to reference Palmu AA, Verho J, Jokinen J, Karma P, Kilpi TM. The seven-valent pneumococcal conjugate vaccine reduces tympanostomy tube placement in children. Pediatr Infect Dis J. 2004;23(8):732–8.CrossRef Palmu AA, Verho J, Jokinen J, Karma P, Kilpi TM. The seven-valent pneumococcal conjugate vaccine reduces tympanostomy tube placement in children. Pediatr Infect Dis J. 2004;23(8):732–8.CrossRef
Metadata
Title
Incidence of acute otitis media in children in the United States before and after the introduction of 7- and 13-valent pneumococcal conjugate vaccines during 1998–2018
Authors
Tianyan Hu
Nicolae Done
Tanaz Petigara
Salini Mohanty
Yan Song
Qing Liu
Esteban Lemus-Wirtz
James Signorovitch
Eric Sarpong
Thomas Weiss
Publication date
01-12-2022
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2022
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-022-07275-9

Other articles of this Issue 1/2022

BMC Infectious Diseases 1/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.